Sparks commentary

Healthcare

Sparks

Isofol Medical (ST: ISOFOL) completes pre-IND meeting for arfolitixorin
Published by Arron Aatkar, PhD

Isofol Medical has announced the completion of a pre-IND meeting with the FDA for arfolitixorin. According to management, the meeting was a success, with the FDA providing positive feedback on the company’s clinical development plan for the candidate. This is an important milestone for Isofol, as it provides a foundation for further development efforts and potential eventual commercialisation in the US.

Isofol is currently evaluating arfolitixorin in a Phase Ib/II trial as a potential treatment for patients with metastatic colorectal cancer.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free